Speakers

Expand/Collapse

Nagy Habib
Head of Research and Development
MiNa Therapeutics

Post-Conference Focus Day

Thursday April 7, 2022

2:00 pm | Pre-Clinical and Clinical Delivery to Myeloid Cells and CNS

Dong Wei
Chief Executive Officer
EdiGene

Day Two

Wednesday April 6, 2022

9:10 am | RNA Therapeutics with LEAPER 2.0: Initial Proof of Concept in Preclinical Models including Human Primary Cells, Mice and Nonhuman Primates

Zhen Li
Chief Executive Officer
ADARx

Day Two

Wednesday April 6, 2022

9:40 am | An ADARx Pre-Clinical Model of RNA Editing Therapeutics

Ranjan Batra
Vice President Research and Development
Locanabio

Day Two

Wednesday April 6, 2022

8:40 am | RNA Targeting Gene Therapy for Neuromuscular Disease

Joey Verdi
Co-founder and Chief Scientific Officer
Hepione Therapeutics

Post-Conference Focus Day

Thursday April 7, 2022

1:30 pm | A New Tool for the Delivery of RNA Therapeutics to Specific Target Cells

Paul Vogel
Postdoctoral Researcher
Stanford University

Michael Breen
Assistant Professor
Icahn School of Medicine at Mount Sinai

Day One

Tuesday April 5, 2022

8:40 am | Fundamentals of RNA Editing in the Central Nervous System

Shizuka Uchida
Professor & Co-Director
Aalborg University

Day Two

Wednesday April 6, 2022

4:10 pm | A-I RNA Editing in the Cardiovascular System and Disease

Emanuela Felley- Bosco
Group Leader
University of Zürich

Day Two

Wednesday April 6, 2022

3:40 pm | RNA Editing in Mesothelioma

Erez Levanon
Professor
Bar Ilan University

Day One

Tuesday April 5, 2022

1:40 pm | Global Quantification Exposes Abundant Low-Level Off-Target Activity by Base Editors

Eli Eisenberg
Professor
Tel Aviv University

Day One

Tuesday April 5, 2022

9:10 am | Quantitative Analysis of the Endogenous Editome to Guide Base- Editing Development

Alan Herbert
Founder and Head of Discovery
InsideOutBio

Day Two

Wednesday April 6, 2022

4:40 pm | Panel Discussion: The Future Possibilities of RNA Editing

1:30 pm | Flipons, Editing and Cancer

Amy Lancaster
Principal Scientist, Research
Korro Bio

Day One

Tuesday April 5, 2022

11:10 am | Platform Optimization to Enable Therapeutic Development of ADARMediated RNA Editing

Nina Papavasilou
Professor, Division Head
DKFZ German Cancer Research Centre

Day Two

Wednesday April 6, 2022

4:40 pm | Panel Discussion: The Future Possibilities of RNA Editing

3:10 pm | ADARs, APOEBECS, and tumours: RNA Editing and Disease Manifestations

Robert Goodnow
Vice President Medicinal Chemistry
Stoke Therapeutics

Day One

Tuesday April 5, 2022

11:40 am | Panel Discussion: Chemical Modifications of RNA Editing

Gerard Platenburg
Co-Founder and Chief Innovation Officer
ProQR

Day Two

Wednesday April 6, 2022

11:00 am | Understanding Lessons Learned From AON Clinical Development and Translation to the RNA Base Editing Axiomer Technology

Venkat Krishnamurthy
Executive Director
Eli Lilly

Day One

Tuesday April 5, 2022

4:00 pm | Chair’s Closing Remarks

8:30 am | Chair’s Opening Remarks

Anja Mølhart Høg
Technology Officer, RNA Therapeutics
Roche

Wensheng Wei
Scientific Founder, EdiGene, Professor with tenure and Director
Peking University Genome Editing Research Center

Day One

Tuesday April 5, 2022

1:10 pm | Leaper 2.0: Next Generation of Leveraging Endogenous ADAR for Programmable Editing on RNA

Paul Bolno, MD
President and Chief Executive Officer
Wave Life Sciences

Day Two

Wednesday April 6, 2022

4:40 pm | Panel Discussion: The Future Possibilities of RNA Editing

Post-Conference Focus Day

Thursday April 7, 2022

11:20 am | Morning Q&A and Panel Discussion – Improving Delivery Performance

10:50 am | Unlocking Therapeutic RNA Editing

Andrew Fraley
Founder and Chief Technology Officer
Korro Bio

Day One

Tuesday April 5, 2022

11:40 am | Panel Discussion: Chemical Modifications of RNA Editing

Day Two

Wednesday April 6, 2022

5:10 pm | Chair’s Closing Remarks

8:30 am | Chair’s Opening Remarks

Adrian Briggs
Head of Platform Technologies
Shape Therapeutics

Day One

Tuesday April 5, 2022

9:40 am | RNAfix: Therapeutic RNA Editing with Engineered Guide RNAs and Endogenous ADAR

David J. Huss, PhD
Chief Scientific Officer
Shape Therapeutics

Post-Conference Focus Day

Thursday April 7, 2022

11:20 am | Morning Q&A and Panel Discussion – Improving Delivery Performance

10:20 am | Delivery Considerations for RNA Editing Payloads

Paloma Giangrande
Vice President, Platform Discovery Sciences, Biology
Wave Life Sciences

Day Two

Wednesday April 6, 2022

11:30 am | AIMers: Correcting Driver Mutations for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) and Beyond

Dinah Weismann
Chief Executive Officer & Chief Scientific Officer
Alcediag

Day Two

Wednesday April 6, 2022

4:40 pm | Panel Discussion: The Future Possibilities of RNA Editing

1:00 pm | RNA Editing for Personalized Diagnostics in Neuropsychiatry

Chandra Vargeese, PhD
Chief Technology Officer
Wave Life Sciences

Day One

Tuesday April 5, 2022

11:40 am | Panel Discussion: Chemical Modifications of RNA Editing

Massimiliano Clamer
President & Founder
Immagina Biotechnology

Day One

Tuesday April 5, 2022

2:45 pm | ITN-European Union ROPES Network

Sophia Shamsi
Research Analyst for RNA Editing
Beacon

Day Two

Wednesday April 6, 2022

2:00 pm | Beacon: The RNA Editing Landscape